Triastek
Triastek Files China’s First 3D-Printed Drug NDA: T20j (Apixaban)
Triastek has submitted an NDA for T20j, China’s first 3D-printed drug, marking a regulatory milestone. The filing follows approval of the nation’s first 3D-printing drug manufacturing license and comes alongside Triastek’s broad 3D-printed pipeline and global pharma collaborations.